A small-molecule angiotensin IV analog developed at Washington State University as a candidate for Alzheimer’s disease and neurodegenerative cognitive decline. The preclinical literature is striking. The human clinical literature, as of this writing, does not exist. Here’s an honest read of what the evidence does and does not show.
Regulatory notice: Dihexa is not an FDA-approved drug and is not currently on FDA’s 503A Bulks List. FDA’s Pharmacy Compounding Advisory Committee reviewed a separate group of peptides for the list on July 23–24, 2026; Dihexa was not among them.
This page is educational and is not medical advice. Whether any therapy is appropriate is a clinical decision — talk to a PepScribe clinician to discuss your situation and options.
Dihexa is a small-molecule analog of the angiotensin IV neuropeptide. Its formal chemical name is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, and it is sometimes described as a hexapeptide derivative even though, structurally, it is closer to a dipeptide flanked by two aliphatic chains. The molecule was rationally designed to preserve the procognitive activity of angiotensin IV at the AT4 / IRAP binding site while resisting enzymatic degradation, achieving oral bioavailability, and crossing the blood-brain barrier. Native angiotensin IV does none of those things, which is why it never advanced as a drug candidate.
The compound was developed by Joseph W. Harding and colleagues at Washington State University. Their stated goal was a candidate molecule for Alzheimer’s disease and other forms of neurodegenerative cognitive decline. The mechanistic hypothesis they pursued is that the AT4 receptor system is closely tied to hepatocyte growth factor (HGF) and its receptor c-Met, and that pharmacologically enhancing HGF / c-Met signaling in the hippocampus could restore the synaptic connectivity lost in dementia.
That hypothesis produced some of the more dramatic preclinical neuroscience imagery of the last fifteen years. It has not produced a finished human clinical trial.
McCoy et al. (2013, Journal of Pharmacology and Experimental Therapeutics) proposed that Dihexa potentiates HGF activity at the c-Met receptor, the receptor tyrosine kinase implicated in cell growth, motility, and synaptic plasticity. In cell-culture systems lacking HGF, Dihexa had no effect on dendritic spine formation, which the authors interpreted as evidence that the compound’s activity is HGF-dependent rather than receptor-independent.
In dissociated rat hippocampal neuron cultures, Benoist, Wright et al. (2011, Journal of Pharmacology and Experimental Therapeutics) reported a dose-dependent increase in dendritic spine density in cells exposed to Dihexa, with reported potency several orders of magnitude greater than the parent angiotensin IV molecule. Spine density is a proxy measure for excitatory synaptic connectivity. The cell-culture finding is striking but does not, on its own, establish a clinical effect on memory in living humans.
Most peptides degrade in the gut and cannot be dosed orally. The aliphatic modifications at both termini of Dihexa were specifically engineered to resist proteolysis and enable oral absorption in rodents. Wright and Harding (2015, Frontiers in Endocrinology) summarized the design rationale: peptide-like pharmacology, drug-like distribution. Whether the rodent oral pharmacokinetics translate to humans has not been formally tested in a published trial.
The Harding lab characterized Dihexa as blood-brain-barrier-penetrant in rodent models, which is the necessary condition for any orally dosed cognitive therapeutic. Combined with reported potency at the HGF / c-Met pathway, this property is the basis for the compound’s preclinical interest. It is also the reason its safety profile deserves particular scrutiny: an orally bioavailable, CNS-penetrant pro-growth signaling agent is a higher-stakes intervention than a peripheral peptide.
All four of the mechanistic findings above come from preclinical work (cell culture and rodent models), led primarily by the Harding group and a small number of collaborators. Independent replication outside the originating laboratories is limited.
Dihexa’s reputation has spread through the nootropic community on the strength of its preclinical results. The literature itself is narrower and more cautious than the secondary discussion around it.
Benoist et al. (2011) and follow-up work from the Harding lab demonstrated increased dendritic spine formation in hippocampal neuron cultures exposed to Dihexa. The reported potency in vitro was substantially greater than the parent angiotensin IV. This is the foundational neurobiological observation behind the compound’s reputation, and it is a cell-culture result, not a clinical outcome.
McCoy et al. (2013) and related work tested Dihexa in standard rodent cognition paradigms, including the Morris water maze and scopolamine-induced amnesia models. Treated rats showed improved spatial memory performance compared to controls in those specific assays. These are validated preclinical screens for cognitive-enhancing compounds, but a rodent maze result does not establish efficacy or safety in human Alzheimer’s disease, traumatic brain injury, or cognitive aging.
Reviews from the originating laboratory (Wright and Harding, 2015, Frontiers in Endocrinology) sketched a theoretical case for Dihexa in Alzheimer’s disease, traumatic brain injury, and other conditions characterized by lost synaptic connectivity. These are research hypotheses consistent with the preclinical mechanism, not established indications.
As of this writing there are no completed, peer-reviewed human clinical trials of Dihexa. No published phase 1 safety study, no phase 2 efficacy data in Alzheimer’s disease, no controlled trial in any cognitive indication. The compound’s reputation rests on preclinical promise plus several years of online nootropic-community use, not clinical evidence. Anyone reading user-reported anecdotes should weight that distinction heavily.
In the published preclinical work, Dihexa was administered orally and via intracerebroventricular injection in rodents to characterize its central nervous system activity. Because the molecule was designed for oral bioavailability, its rodent pharmacokinetic profile is structured around oral dosing rather than injection.
There is no FDA-approved dosing protocol, no validated human pharmacokinetic profile, and no consensus on dosing in any clinical population. Research-channel products labeled as Dihexa carry no pharmaceutical-grade quality assurance, no established potency, and no impurity controls. Users in the nootropic community have reported a wide range of self-administered doses with no underlying clinical rationale.
This is research context, not prescribing guidance. Dihexa is handled consultation-first, and this information should not be interpreted as a dosing recommendation.
The thinness of the human safety record is the most important fact about this compound. The mechanism itself also carries theoretical concerns that deserve to be named explicitly.
There are no completed phase 1 safety trials in humans. Self-reported adverse effects in nootropic-community use have included headache, lightheadedness, and blood pressure changes, but these reports are not from controlled studies and cannot establish an incidence rate, a dose-response curve, or a long-term safety profile. The absence of evidence here is not the same thing as evidence of safety.
The HGF / c-Met signaling axis is well-characterized in oncology because c-Met activation is a documented driver of cell proliferation, migration, and angiogenesis in multiple solid tumors (see review by Trusolino, Bertotti, and Comoglio, 2010, Nature Reviews Molecular Cell Biology). Any compound that potentiates HGF activity at c-Met inherits a theoretical concern about pro-tumor signaling, particularly in patients with undiagnosed malignancy. This has not been ruled out clinically because no clinical safety program has been conducted. It is a mechanism-level flag, not a confirmed harm.
Dihexa was designed to cross the blood-brain barrier and engage a pro-growth / pro-angiogenic pathway. That combination is exactly what makes the compound pharmacologically interesting, and it is exactly why the absent human safety record matters. A peripheral peptide with limited CNS exposure is a different risk calculation than an orally bioavailable, brain-penetrant signaling agent acting on a pathway with known oncology implications.
Dihexa sold through research-chemical suppliers is not pharmaceutical-grade. No potency assay, no impurity profile, no sterility testing, no chain-of-custody. Users in the nootropic community are dosing material whose identity, purity, and stability cannot be verified, and they are doing so without the human safety data that would normally support any cognitive therapeutic.
Consult a healthcare provider before considering any peptide therapy. This information is educational and does not replace medical advice.
Dihexa is not an FDA-approved drug for any indication. It has never received an FDA approval, and there is no public record of a sponsor-led IND program reaching completion in humans.
On April 15, 2026, the FDA published a list of peptide compounds (often referred to as the transitional list) that were removed from the prior Category 2 status but not placed onto Category 1, pending review by the Pharmacy Compounding Advisory Committee. Dihexa Acetate is on that list. The compound’s regulatory posture is therefore ambiguous: removal from Category 2 lifts the prior compounding prohibition, but Dihexa Acetate has not been affirmatively cleared for pharmaceutical or compounding use either.
Material sold under the Dihexa name today moves primarily through research-chemical channels. These products are not regulated as drugs, are not subject to current Good Manufacturing Practice (cGMP) requirements, and are sold for in-vitro research only. Dihexa is not currently on FDA’s 503A Bulks List, and PepScribe handles it consultation-first rather than as a peptide-direct product.
Supports cellular energy production, cognitive function, and neuroprotection. NAD+ is fundamental to brain energy metabolism and the sirtuins that protect neuronal DNA. Physician-prescribed and delivered to your door.
Get startedGrowth hormone-releasing peptide. GH supports deep sleep (when the brain consolidates memory), cognitive recovery, and neuronal repair processes. Physician-prescribed.
Get startedDeep dives
Research-backed articles covering specific topics in depth.
The post does the arithmetic openly: rat oral doses of 1.25 to 2.9 mg/kg scale to roughly 7.6 to 17.5 mg for a 75 kg adult, then concedes that low oral bioavailability undercuts the estimate. Allometric scaling from rodent data is a hypothesis rather than a human dose, and no commenter supplies human data to test it; dihexa is not FDA-approved, so every number attached to it remains an extrapolation.
Posted on Reddit
Dihexa is Category-unclassified with no completed human trials. PepScribe’s assessment routes you to a clinician-led conversation about evidence-supported options.
